NASDAQ:HZNP - Horizon Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.22 +0.30 (+1.37 %) (As of 01/17/2019 04:00 PM ET)Previous Close$21.92Today's Range$21.62 - $22.6652-Week Range$12.55 - $23.38Volume1.37 million shsAverage Volume1.27 million shsMarket Capitalization$3.71 billionP/E Ratio18.83Dividend YieldN/ABeta0.94 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. Receive HZNP News and Ratings via Email Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP Previous Symbol CUSIP44047T10 Webwww.horizonpharma.com Phone011-353-1772-2100Debt Debt-to-Equity Ratio2.06 Current Ratio1.94 Quick Ratio1.86Price-To-Earnings Trailing P/E Ratio18.83 Forward P/E Ratio17.09 P/E Growth1.09 Sales & Book Value Annual Sales$1.06 billion Price / Sales3.53 Cash Flow$3.0606 per share Price / Cash Flow7.26 Book Value$6.05 per share Price / Book3.67Profitability EPS (Most Recent Fiscal Year)$1.18 Net Income$-410,520,000.00 Net Margins-18.70% Return on Equity27.14% Return on Assets6.09%Miscellaneous Employees1,010 Outstanding Shares167,630,000Market Cap$3.71 billion OptionableOptionable Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions What is Horizon Pharma's stock symbol? Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP." How will Horizon Pharma's stock buyback program work? Horizon Pharma declared that its Board of Directors has approved a share buyback program on Sunday, June 4th 2017, which authorizes the company to buyback 1,000% of outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its stock is undervalued. How were Horizon Pharma's earnings last quarter? Horizon Pharma PLC (NASDAQ:HZNP) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported $0.65 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.15. The biopharmaceutical company had revenue of $325.30 million for the quarter, compared to analysts' expectations of $311.84 million. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The company's quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.26 EPS. View Horizon Pharma's Earnings History. When is Horizon Pharma's next earnings date? Horizon Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Horizon Pharma. What guidance has Horizon Pharma issued on next quarter's earnings? Horizon Pharma updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.17-1.2 billion, compared to the consensus revenue estimate of $1.18 billion. What price target have analysts set for HZNP? 12 analysts have issued 1 year price targets for Horizon Pharma's shares. Their forecasts range from $18.00 to $35.00. On average, they anticipate Horizon Pharma's stock price to reach $23.7273 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Horizon Pharma. What is the consensus analysts' recommendation for Horizon Pharma? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Pharma in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Pharma. What are Wall Street analysts saying about Horizon Pharma stock? Here are some recent quotes from research analysts about Horizon Pharma stock: 1. Mizuho analysts commented, "We reiterate our Buy rating on Krystexxa momentum and upcoming teprotumumab Phase III data (expected 2Q:19)." (11/7/2018) 2. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for HZNP shares to $23 from $21. The increase in our PT is driven by multiple expansion. We think this is deserved because continued solid execution from the management team underscores our belief that the peak sales potential of HZNP’s orphan/rare disease as well as rheumatology businesses are underappreciated." (10/18/2018) 3. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018) 4. According to Zacks Investment Research, "Horizon Pharma’s orphan and rheumatology business units witnessed strong growth. We expect Krystexxa, Ravicti and Actimmune to drive further growth. The acquisition of teprotumumab has further diversified the company’s portfolio. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. In June 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in Europe, the Middle East and Africa to Chiesi Farmaceutici S.p.A. to focus on higher return businesses. Shares of the company have outperformed the industry so far this year." (7/17/2018) Has Horizon Pharma been receiving favorable news coverage? Headlines about HZNP stock have trended negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Horizon Pharma earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next few days. Who are some of Horizon Pharma's key competitors? Some companies that are related to Horizon Pharma include Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO) and Dr.Reddy's Laboratories (RDY). Who are Horizon Pharma's key executives? Horizon Pharma's management team includes the folowing people: Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 49)Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 54) Who are Horizon Pharma's major shareholders? Horizon Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sheets Smith Wealth Management (0.01%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Geoffrey M Curtis, Michael G Grey, Robert Carey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma. Which major investors are buying Horizon Pharma stock? HZNP stock was acquired by a variety of institutional investors in the last quarter, including Sheets Smith Wealth Management and Meeder Asset Management Inc.. View Insider Buying and Selling for Horizon Pharma. How do I buy shares of Horizon Pharma? Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Horizon Pharma's stock price today? One share of HZNP stock can currently be purchased for approximately $22.22. How big of a company is Horizon Pharma? Horizon Pharma has a market capitalization of $3.71 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe. What is Horizon Pharma's official website? The official website for Horizon Pharma is http://www.horizonpharma.com. How can I contact Horizon Pharma? Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected] MarketBeat Community Rating for Horizon Pharma (NASDAQ HZNP)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 707 (Vote Outperform)Underperform Votes: 333 (Vote Underperform)Total Votes: 1,040MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: What is an investor looking for in an SEC filing?